Cristina Puy

Cristina Puy

Auto-generated profile, based on publicly available information

Cristina Puy

Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
CPC. Puy
C. Puy
ETE. I. Tucker
E. I. Tucker
ZWZ. C. Wong
Z. C. Wong
DGD. Gailani
D. Gailani
SSS. A. Smith
S. A. Smith
OMO. J. T. McCarty
O. J. T. McCarty
Background Inorganic polyphosphates (polyP), which are secreted by activated platelets (short‐chain polyP) and accumulate in some bacteria (long‐chain polyP), support the contact activation of factor XII (FXII) and accelerate the activation of FXI. Objectives The aim of the present study was to evaluate the role of FXI in polyP‐mediated coagulation activation and experimental thrombus formation. Methods and Results Pretreatment of plasma with antibodies that selectively inhibit FXI activation by activated FXII (FXIIa) or FIX) activation by activated FXI (FXIa) were not able to inhibit the procoagulant effect of long or short‐chain polyP in plasma. In contrast, the FXIIa inhibitor, corn trypsin inhibitor, blocked the procoagulant effect of long and short polyP in plasma. In a purified system, long polyP significantly enhanced the rate of FXII and prekallikrein activation and the activation of FXI by thrombin but not by FXIIa. In FXI‐deficient plasma, long polyP promoted clotting of plasma in an FIX‐dependent manner. In a purified system, the activation of FXII and prekallikrein by long polyP promoted FIX activation and prothombin activation. In an ex vivo model of occlusive thrombus formation, inhibition of FXIIa with corn trypsin inhibitor but not of FXI with a neutralizing antibodies abolished the prothrombotic effect of long polyP. Conclusions We propose that long polyP promotes FXII‐mediated blood coagulation bypassing FXI. Accordingly, some polyp‐containing pathogens may have evolved strategies to exploit polyP‐initiated FXII activation for virulence, and selective inhibition of FXII may improve the host response to pathogens.

1 May 2016 in Thrombosis Research
Verified
Journal Article
Closed access
CPCristina Puy
Cristina Puy
RRRachel A. Rigg
Rachel A. Rigg
OMOwen J.T. McCarty
Owen J.T. McCarty

15 April 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CPCristina Puy
Cristina Puy
JPJiaqing Pang
Jiaqing Pang
SRStéphanie E Reitsma
Stéphanie E Reitsma
CLChristina U. Lorentz
Christina U. Lorentz
ETErik I Tucker
Erik I Tucker
OMOwen J. T. McCarty
Owen J. T. McCarty
Complement factor H (CFH) is the major inhibitor of the alternative pathway of the complement system and is structurally related to beta2-glycoprotein I, which itself is known to bind to ligands, including coagulation factor XI (FXI). We observed reduced complement activation when FXI activation was inhibited in a baboon model of lethal systemic inflammation, suggesting cross-talk between FXI and the complement cascade. It is unknown whether FXI or its activated form, activated FXI (FXIa), directly interacts with the complement system. We explored whether FXI could interact with and inhibit the activity of CFH. We found that FXIa neutralized CFH by cleavage of the R341/R342 bonds. FXIa reduced the capacity of CFH to enhance the cleavage of C3b by factor I and the decay of C3bBb. The binding of CFH to human endothelial cells was also reduced after incubating CFH with FXIa. The addition of either short- or long-chain polyphosphate enhanced the capacity of FXIa to cleave CFH. FXIa also cleaved CFH that was present on endothelial cells and in the secretome from blood platelets. The generation of FXIa in plasma induced the cleavage of CFH. Moreover, FXIa reduced the cleavage of C3b by factor I in serum. Conversely, we observed that CFH inhibited FXI activation by either thrombin or FXIIa. Our study provides, to our knowledge, a novel molecular link between the contact pathway of coagulation and the complement system. These results suggest that FXIa generation enhances the activity of the complement system and thus may potentiate the immune response.

11 April 2024 in Blood
Verified
Journal Article
Closed access
PDF file
SMSamantha A. Moellmer
Samantha A. Moellmer
CPCristina Puy
Cristina Puy
OMOwen J. T. McCarty
Owen J. T. McCarty
Unique among coagulation factors, the coagulation factor XI (FXI) arose through a duplication of the gene KLKB1, which encodes plasma prekallikrein. This evolutionary origin sets FXI apart structurally because it is a homodimer with 2 identical subunits composed of 4 apple and 1 catalytic domain. Each domain exhibits unique affinities for binding partners within the coagulation cascade, regulating the conversion of FXI to a serine protease as well as the selectivity of substrates cleaved by the active form of FXI. Beyond serving as the molecular nexus for the extrinsic and contact pathways to propagate thrombin generation by way of activating FIX, the function of FXI extends to contribute to barrier function, platelet activation, inflammation, and the immune response. Herein, we critically review the current understanding of the molecular biology of FXI, touching on some functional consequences at the cell, tissue, and organ level. We conclude each section by highlighting the DNA mutations within each domain that present as FXI deficiency. Together, a narrative review of the structure-function of the domains of FXI is imperative to understand the etiology of hemophilia C as well as to identify regions of FXI to safely inhibit the pathological function of activation or activity of FXI without compromising the physiologic role of FXI.

10 February 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
ANAnh T. P. Ngo
Anh T. P. Ngo
KJKelley R. Jordan
Kelley R. Jordan
PMPaul A. Mueller
Paul A. Mueller
MHMatthew W. Hagen
Matthew W. Hagen
SRStéphanie E. Reitsma
Stéphanie E. Reitsma
OMOwen J.T. McCarty
Owen J.T. McCarty

24 October 2024 in Blood
Verified
Journal Article
Closed access
CPCristina Puy
Cristina Puy
SMSamantha A. Moellmer
Samantha A. Moellmer
JPJiaqing Pang
Jiaqing Pang
HVHelen H. Vu
Helen H. Vu
AMAlexander R. Melrose
Alexander R. Melrose
OMOwen J. T. McCarty
Owen J. T. McCarty
Loss of endothelial barrier function contributes to the pathophysiology of many inflammatory diseases. Coagulation factor XI (FXI) plays a regulatory role in inflammation. Although activation of FXI increases vascular permeability in vivo, the mechanism by which FXI or its activated form FXIa disrupts endothelial barrier function is unknown. We investigated the role of FXIa in human umbilical vein endothelial cell (HUVEC) or human aortic endothelial cell (HAEC) permeability. The expression patterns of vascular endothelial (VE)-cadherin and other proteins of interest were examined by western blot or immunofluorescence. Endothelial cell permeability was analyzed by Transwell assay. We demonstrate that FXIa increases endothelial cell permeability by inducing cleavage of the VE-cadherin extracellular domain, releasing a soluble fragment. The activation of a disintegrin and metalloproteinase 10 (ADAM10) mediates the FXIa-dependent cleavage of VE-cadherin, because adding an ADAM10 inhibitor prevented the cleavage of VE-cadherin induced by FXIa. The binding of FXIa with plasminogen activator inhibitor 1 and very low–density lipoprotein receptor on HUVEC or HAEC surfaces activates vascular endothelial growth receptor factor 2 (VEGFR2). The activation of VEGFR2 triggers the mitogen-activated protein kinase (MAPK) signaling pathway and promotes the expression of active ADAM10 on the cell surface. In a pilot experiment using an established baboon model of sepsis, the inhibition of FXI activation significantly decreased the levels of soluble VE-cadherin to preserve barrier function. This study reveals a novel pathway by which FXIa regulates vascular permeability. The effect of FXIa on barrier function may be another way by which FXIa contributes to the development of inflammatory diseases.